null

null

null

null

null

null

null

null

null

null

null

null

null

0.41x Total Debt / Equity (Conservative)

Assertio carries ~$130M in fixed-rate convertible notes; a 200bps rise has minimal direct P&L impact but pressures refinancing cost and equity dilution risk at maturity.

Low intensity; China and India supply >60% of global API inputs, creating concentration risk.

Single-source API manufacturers (primarily India and China-based CMOs); Indian generic API manufacturing concentration is primary chokepoint, Chinese chemical precursors secondary.

Assertio derives ~95%+ revenue domestically; international revenue is negligible, so sovereign currency devaluation exposure across foreign markets is effectively near-zero.

Nearly 100% U.S. domestic revenue; no material international market exposure, making sovereign currency devaluation risk essentially non-applicable for this company.

Low intensity; commodities: Active Pharmaceutical Ingredients, Rare Earth Elements, Natural Gas (energy), Plastics/Resins, Ethanol, Packaging Materials; geopolitical: China and India supply >60% of global API inputs, creating concentration risk.

Yes; single-source contract manufacturers for ROLVEDON and Sympazan represent non-substitutable supply relationships exceeding 30% of COGS, creating high vendor lock risk.

Assertio is a specialty pharma company, not cloud-dependent; a cloud provider termination would cause operational disruption but business continuity via rapid migration is feasible within 30-60 days.

Secondary systems (ERP, CRM, compliance databases) are likely multi-vendor; cloud termination risk is moderate but not existential given small commercial infrastructure footprint.

Low API coupling risk; Assertio uses standard pharma commercial software (Veeva, IQVIA); no proprietary API dependencies creating hard switching lock-in.

Fails Howey Test; Assertio's revenue derives from FDA-approved drug sales to patients/payers, not investment contracts — Howey Test not applicable, securities risk index near zero.

Very High

Moderate HIPAA exposure on patient data; CCPA applies to California HCP/patient interactions; GDPR exposure minimal given negligible EU operations.

Low-to-moderate; Assertio holds niche branded drug positions without dominant market share; no known FTC pricing investigations but branded drug pricing faces ongoing congressional scrutiny.

Very High burden; regimes: FDA, CMS, HHS, HIPAA, EMA, OIG; Drug pricing legislation and approval delays directly compress revenue visibility.

Predominantly transactional; ~80-90% revenue from prescription drug product sales; small royalty/licensing streams provide modest recurring component (~10-15%).

Primary monetization via branded and generic prescription drug product sales through specialty pharmacy and wholesaler channels; secondary via royalties and licensing agreements.

WAC-based branded drug pricing with rebate/contract concessions to PBMs; pricing power constrained by formulary negotiation, generic competition, and IRA drug pricing reform pressure.

Weak-to-moderate; ROLVEDON faces biosimilar/competitive pressure; Sympazan in competitive CDSM space; IRA and PBM dynamics further compress net price realization over 3-5 years.

Gross margins estimated 70-80% on branded products; blended company gross margin approximately 65-75% after COGS including royalties and manufacturing costs.

No free-rider problem; prescription drugs require physician authorization and pharmacy dispensing — access is gated; churn risk is formulary delisting or physician switching, not free-riding.

Sublinear; Assertio operates a lean commercial model with contract sales force options; doubling revenue via new products does not require proportional headcount doubling given outsourced infrastructure.

Marginal growth cost is primarily manufacturing COGS and distribution; SG&A leverage is achievable; adding new products to existing commercial infrastructure yields positive operating leverage.

Not applicable; Assertio is not a franchise business model — no franchise network compliance drift risk exists.

At 10x scale, HCP detailing cost efficiency improves but payer rebate concessions scale proportionally; customer acquisition cost per script likely decreases 30-40% via salesforce leverage.

No network effects; prescription pharmaceutical sales are transactional with no user-to-user value amplification; growth is linear to sales force reach and formulary access.

-11.2% Return on Assets (Negative equity)

Moderate-high recession resistance; branded specialty drugs for pain/epilepsy have inelastic demand, but uninsured/underinsured patients may reduce adherence during economic downturns.

Specialty physicians (neurologists, pain specialists, oncologists) and hospitals; high concentration risk — top 20% of prescribers likely drive 80%+ of volume.

Pharmacy benefit managers (PBMs) and GPOs as institutional customers; top 3 PBMs (CVS Caremark, Express Scripts, OptumRx) control formulary access, creating significant buyer concentration risk.

["11-0000 Management Occupations", "13-0000 Business and Financial Operations Occupations", "15-0000 Computer and Mathematical Occupations", "19-0000 Life, Physical, and Social Science Occupations", "21-0000 Community and Social Service Occupations", "23-0000 Legal Occupations", "29-0000 Healthcare Practitioners and Technical Occupations", "31-0000 Healthcare Support Occupations", "41-0000 Sales and Related Occupations", "43-0000 Office and Administrative Support Occupations", "51-0000 Production Occupations"]

0.32 (HIL — ~32% of characteristic roles agent-automatable)

0.0% CapEx / Revenue (Low-CapEx Asset-Light)

0001808665

ASRT